Industrial Instruments For Measurement, Display, and Control
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, municipal, industrial, and natural resource applications. It also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. The company was founded in 1969 and is headquartered in Washington, the District of Columbia.
Discounted Cash Flow Valuation of Danaher Corp
Growth
%
%
Discount
%
%
Multiple
g\r | +10% | +11% | +12% | +13% | +14% |
---|---|---|---|---|---|
0% | 10 | 9 | 8 | 8 | 7 |
+1% | 11 | 10 | 9 | 8 | 8 |
+2% | 13 | 11 | 10 | 9 | 8 |
+3% | 14 | 13 | 11 | 10 | 9 |
+4% | 17 | 14 | 12 | 11 | 10 |
Years | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | TV |
---|---|---|---|---|---|---|---|---|---|---|---|---|
FCF | $5.557B | $6.279B | $7.04B | $7.83B | $8.639B | $9.455B | $10.26B | $11.05B | $11.8B | $12.49B | $13.12B | $131.2B |
DCF | $5.46B | $5.323B | $5.148B | $4.939B | $4.701B | $4.437B | $4.154B | $3.857B | $3.552B | $3.243B | $32.43B | |
Value | $77.24B |
In the chart Earnings are multiplied by this value.
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
---|---|---|---|---|---|---|---|---|---|---|
Net Margin | 16% | 15% | 14% | 13% | 16% | 16% | 21% | 23% | 20% | 20% |
ROA | 7.2% | 6.1% | 6.5% | 7.1% | 5.3% | 5.9% | 9.1% | 10% | 6.2% | 5.7% |
ROE | 14% | 11% | 9.5% | 9.4% | 9.7% | 8.8% | 14% | 14% | 8.9% | 8.2% |
The average Net Margin over the past 5 years is +18.2%.
The trend of Net Margin over the past 5 years is +1.62%.
The average ROA over the past 5 years is +7.32%.
The trend of ROA over the past 5 years is +0.38%.
The average ROE over the past 5 years is +10.81%.
The trend of ROE over the past 5 years is +0.45%.
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
---|---|---|---|---|---|---|---|---|---|---|
Debt FCF | 4.29 | 5.07 | 3.75 | 2.91 | 6.62 | 3.91 | 3.14 | 2.75 | 3.48 | 3.58 |
Debt Equity | 0.58 | 0.64 | 0.41 | 0.35 | 0.72 | 0.53 | 0.49 | 0.40 | 0.38 | 0.37 |
MIN | ||||||||||
Graham Stability | - | - | 88% | 95% | 100% | 100% | 100% | 100% | 84% | 84% |
The Debt/FCF trailing twelve month is 3.58.
The trend of Debt/FCF over the past 5 years is -0.27.
Graham’s Stability measure stands at 0.84.
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
Years | 12-2016 | 12-2018 | 12-2020 | 12-2022 | Trend |
---|---|---|---|---|---|
Revenue | 5.1% | 3.7% | 2.3% | -24% | 0.47% |
Net Income | 9.2% | 12% | 11% | -33% | 0.62% |
Stockholders Equity | 13% | 14% | 10% | 6.8% | 1.4% |
FCF | 10% | 11% | 2.1% | -22% | 0.97% |
The Revenue CAGR over the past 5 years is +3.73%.
The trend of Revenue growth rate over the past 5 years is +0.47%.
The Earnings CAGR over the past 5 years is +12.34%.
The trend of Earnings growth rate over the past 5 years is +0.62%.
The Equity CAGR over the past 5 years is +13.64%.
The trend of Equity growth rate over the past 5 years is +1.43%.
The FCF CAGR over the past 5 years is +11.42%.
The trend of FCF growth rate over the past 5 years is +0.97%.